دورية أكاديمية
أعرض في EDS

Combined Application of Cold Physical Plasma and Chemotherapeutics against Chondrosarcoma Cells.

التفاصيل البيبلوغرافية
العنوان: Combined Application of Cold Physical Plasma and Chemotherapeutics against Chondrosarcoma Cells.
المؤلفون: Nitsch A; Center for Orthopedics, Trauma Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany., Qarqash S; Center for Orthopedics, Trauma Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany., Schulze F; Center for Orthopedics, Trauma Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany., Nonnenmacher L; Center for Orthopedics, Trauma Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany., Bekeschus S; ZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Felix-Hausdorff-Straße 2, 17489 Greifswald, Germany.; Clinic and Policlinic for Dermatology and Venerology, Rostock University Medical Center, Strempelstr. 13, 18057 Rostock, Germany., Tzvetkov MV; Department of General Pharmacology, Institute of Pharmacology, Center of Drug Absorption and Transport (C_DAT), University Medicine Greifswald, 17487 Greifswald, Germany., Wassilew GI; Center for Orthopedics, Trauma Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany., Haralambiev L; Center for Orthopedics, Trauma Surgery and Rehabilitation Medicine, University Medicine Greifswald, Ferdinand-Sauerbruch-Str., 17475 Greifswald, Germany.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 25; Vol. 25 (13). Date of Electronic Publication: 2024 Jun 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Chondrosarcoma*/drug therapy , Chondrosarcoma*/pathology , Plasma Gases*/pharmacology , Cell Proliferation*/drug effects , Doxorubicin*/pharmacology , Apoptosis*/drug effects , Cell Survival*/drug effects , Bone Neoplasms*/drug therapy , Bone Neoplasms*/pathology , Bone Neoplasms*/therapy, Humans ; Cell Line, Tumor ; Antineoplastic Agents/pharmacology ; Cisplatin/pharmacology ; Vincristine/pharmacology ; Combined Modality Therapy
مستخلص: Chondrosarcoma (CS) is a rare malignant bone sarcoma that primarily affects cartilage cells in the femur and pelvis. While most subtypes exhibit slow growth with a very good prognosis, some aggressive subtypes have a poorer overall survival. CS is known for its resistance to chemotherapy and radiotherapy, leaving surgery as the sole effective therapeutic option. Cold physical plasma (CPP) has been explored in vitro as a potential therapy, demonstrating positive anti-tumor effects on CS cells. This study investigated the synergistic effects of combining CPP with cytostatics on CS cells. The chemotherapeutic agents cisplatin, doxorubicin, and vincristine were applied to two CS cell lines (CAL-78 and SW1353). After determining their IC 20 and IC 50 , they were combined with CPP in both cell lines to assess their impact on the cell proliferation, viability, metabolism, and apoptosis. This combined approach significantly reduced the cell proliferation and viability while increasing the apoptosis signals compared to cytostatic therapy alone. The combination of CPP and chemotherapeutic drugs shows promise in targeting chemoresistant CS cells, potentially improving the prognosis for patients in clinical settings.
References: J Am Acad Orthop Surg. 2021 Jul 1;29(13):553-562. (PMID: 33595238)
Biotechnol Bioeng. 2014 Mar;111(3):565-74. (PMID: 24022746)
Mol Cancer. 2009 May 15;8:28. (PMID: 19445670)
PLoS One. 2016 Sep 01;11(9):e0160667. (PMID: 27584003)
Surg Oncol. 2018 Sep;27(3):402-408. (PMID: 30217294)
Biomolecules. 2020 Jul 08;10(7):. (PMID: 32650505)
Biomedicines. 2023 Feb 17;11(2):. (PMID: 36831137)
Cancer. 1977 Aug;40(2):818-31. (PMID: 890662)
Iran J Pharm Res. 2022 Aug 09;21(1):e124106. (PMID: 36942058)
Sci Rep. 2015 Dec 17;5:18339. (PMID: 26677750)
Free Radic Biol Med. 2022 Aug 20;189:32-41. (PMID: 35843475)
Biomedicines. 2022 Mar 17;10(3):. (PMID: 35327489)
Front Pharmacol. 2023 Aug 11;14:1199292. (PMID: 37637411)
Anticancer Res. 2020 Feb;40(2):841-846. (PMID: 32014927)
Mutat Res Genet Toxicol Environ Mutagen. 2016 Mar;798-799:48-54. (PMID: 26994493)
Rep Biochem Mol Biol. 2022 Jan;10(4):640-652. (PMID: 35291609)
J Bone Joint Surg Br. 2002 Jan;84(1):93-9. (PMID: 11837841)
J Orthop Res. 1998 Sep;16(5):585-90. (PMID: 9820282)
Anticancer Res. 2017 Dec;37(12):6739-6744. (PMID: 29187451)
Free Radic Biol Med. 2023 Nov 20;209(Pt 2):202-210. (PMID: 37890599)
Cancers (Basel). 2020 Sep 16;12(9):. (PMID: 32947888)
Cancers (Basel). 2019 Dec 13;11(12):. (PMID: 31847101)
Biomol Ther (Seoul). 2023 Sep 1;31(5):496-514. (PMID: 37641880)
Biochem Biophys Res Commun. 2006 Jul 28;346(2):379-85. (PMID: 16765318)
Cancers (Basel). 2023 Dec 31;16(1):. (PMID: 38201628)
Ann Surg Oncol. 2018 Jan;25(1):299-307. (PMID: 29139022)
Cell Death Dis. 2018 Dec 5;9(12):1179. (PMID: 30518936)
Int J Mol Sci. 2020 Oct 15;21(20):. (PMID: 33076565)
Int J Mol Sci. 2020 Mar 26;21(7):. (PMID: 32225067)
Diagnostics (Basel). 2020 Apr 11;10(4):. (PMID: 32290487)
Sci Rep. 2020 Jul 16;10(1):11788. (PMID: 32678153)
Proc Natl Acad Sci U S A. 2021 Dec 21;118(51):. (PMID: 34916286)
Ann Oncol. 2012 Jun;23(6):1617-26. (PMID: 22112972)
Biomedicines. 2023 Jan 14;11(1):. (PMID: 36672716)
J Cell Physiol. 2019 May;234(5):6778-6782. (PMID: 30387137)
Clin Orthop Relat Res. 2007 Jun;459:40-7. (PMID: 17414166)
ACS Appl Bio Mater. 2022 Apr 18;5(4):1610-1623. (PMID: 35324138)
Free Radic Biol Med. 2021 Aug 1;171:302-313. (PMID: 34022401)
Cancers (Basel). 2020 Jan 22;12(2):. (PMID: 31979114)
Cancers (Basel). 2021 May 14;13(10):. (PMID: 34069269)
Anticancer Res. 2018 Oct;38(10):5655-5663. (PMID: 30275184)
Nat Rev Cancer. 2011 Feb;11(2):85-95. (PMID: 21258394)
J Clin Med. 2023 Mar 26;12(7):. (PMID: 37048590)
Skin Res Technol. 2024 Jan;30(1):e13544. (PMID: 38174746)
Int J Mol Sci. 2023 May 12;24(10):. (PMID: 37240019)
PLoS One. 2013 May 21;8(5):e64498. (PMID: 23704990)
Crit Rev Oncol Hematol. 2018 Jun;126:32-36. (PMID: 29759564)
Ann Oncol. 2013 Nov;24(11):2916-22. (PMID: 24099780)
Sci Rep. 2020 Oct 5;10(1):16495. (PMID: 33020527)
Free Radic Biol Med. 2017 Sep;110:280-290. (PMID: 28666851)
J Biotechnol. 2010 Dec;150(4):530-8. (PMID: 20959125)
Skeletal Radiol. 2023 Mar;52(3):329-348. (PMID: 35852560)
Molecules. 2021 Jul 13;26(14):. (PMID: 34299530)
Eur J Surg Oncol. 2018 Sep;44(9):1412-1418. (PMID: 29929901)
Lancet Oncol. 2005 Aug;6(8):599-607. (PMID: 16054571)
Acta Oncol. 2023 Feb;62(2):110-117. (PMID: 36856035)
Cell Metab. 2018 Dec 4;28(6):848-865.e6. (PMID: 30174307)
Sci Rep. 2021 Jul 20;11(1):14788. (PMID: 34285268)
PLoS One. 2019 Apr 9;14(4):e0215099. (PMID: 30964925)
Int J Mol Sci. 2022 Feb 01;23(3):. (PMID: 35163620)
Biol Chem. 2018 Dec 19;400(1):19-38. (PMID: 30403650)
Oncotarget. 2017 Feb 28;8(9):15977-15995. (PMID: 27845910)
Cancer Diagn Progn. 2022 Nov 3;2(6):681-685. (PMID: 36340450)
فهرسة مساهمة: Keywords: CAP; CPP; NIPP; cancer; cisplatin; cold atmospheric plasma; doxorubicin; medical plasma; vincristine
المشرفين على المادة: 0 (Plasma Gases)
80168379AG (Doxorubicin)
0 (Antineoplastic Agents)
Q20Q21Q62J (Cisplatin)
5J49Q6B70F (Vincristine)
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11241706
DOI: 10.3390/ijms25136955
PMID: 39000064
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25136955